Navigation Links
Relmada Therapeutics Announces LevoCap ER Development Progress
Date:3/4/2013

BLUE BELL, Pa., March 4, 2013 /PRNewswire/ -- Relmada Therapeutics, Inc., a clinical-stage company developing novel therapies for the treatment of chronic pain, today announced the approval of the application of a Clinical Trial Authorization (CTA) that was submitted with the Medicine and Health Regulatory Agency (MHRA) to conduct a Phase I pharmacokinetic study with the development product abuse-deterrent LevoCap extended release (ER) capsules.  The MHRA is the UK government agency which is responsible for ensuring that medicines and medical devices work and are acceptably safe.

This Phase I safety study is designed to assess the bioavailability and dose proportionality of three levorphanol extended release (ER) formulations, how these compare with a marketed IR (immediate release) product available in the US, and whether there are any differences under fed and fasted conditions.

"This significant progress is in line with the development plan of LevoCap ER. If this study shows positive results, then we will be on track to enter the phase III program in the fourth quarter," said Sergio Traversa , CEO of Relmada.

LevoCap ER, Relmada's lead product is intended to add a powerful new tool to treat pain where opioids alone or non-opioids alone do not provide adequate relief.  Unlike other opioids, levorphanol, the active ingredient in LevoCap ER modulates pain through both opioid pathways and noradrenergic pathways thereby providing pain relief through multiple mechanisms in one capsule. Levorphanol has also been shown to partially reverse analgesic tolerance to morphine and may therefore benefit patients who are tolerant to the analgesic effects of their current opioid. 

Based on its pharmacological profile, LevoCap alone should demonstrate improved efficacy in a broader patient population compared to other opioids.  This includes the vast categor
'/>"/>

SOURCE Relmada Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Acquired Orphan Blood Diseases Therapeutics Market to 2019 - Search for Disease Modifying Drugs Central to Unlocking Premium Pricing Potential
2. Autoinjectors to 2018 - Devices, Therapeutics, Markets, Strategies and Prospects
3. Nektar Therapeutics to Present at the 33rd Annual Cowen and Company Healthcare Conference in Boston
4. ADVENTRX Announces Corporate Name Change To "Mast Therapeutics, Inc."; Ticker Symbol Change To "MSTX"
5. Nektar Therapeutics Reports Fourth Quarter and Year-End 2012 Financial Results
6. Orexigen Therapeutics Announces Webcast of Upcoming Presentation at the Cowen & Co. Annual Health Care Conference
7. Takeda and Resolve Therapeutics Enter Autoimmune Partnership
8. Frost & Sullivan Recognizes KAERs Game-Changing Innovating Aerosol Drug Delivery Methods for High-Dose Respiratory Disease Therapeutics
9. United Therapeutics Corporation Reports 2012 Fourth Quarter and Annual Financial Results
10. iBio And Caliber Biotherapeutics Establish License And Collaboration Relationship
11. Elcelyx Therapeutics Completes $20 Million Series C Financing to Advance NewMet and Lovidia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... 2014 Nanomix Inc., (Nanomix), a ... of mobile diagnostic tests to enable earlier ... pre-hospital settings, today announced it has received ... certification was awarded by the British Standards ... certification bodies. ISO 13485:2003 ...
(Date:11/26/2014)... 2014  Breckenridge Pharmaceutical, Inc. announced today that ... with Pii (Pharmaceutics International, Inc.) ( Hunt ... Pii expect to develop and commercialize several new ... will develop, manufacture and supply the products, and ... its own label.  The drugs, comprised of four ...
(Date:11/26/2014)... , Nov. 25, 2014 Halozyme Therapeutics, Inc. (NASDAQ: ... Jaffray Healthcare Conference in New York ... PDT . Dr. Helen Torley , President and ... The presentation will be webcast through the "Investors" section of ... will be made available for 90 days following the event. ...
Breaking Medicine Technology:Nanomix Receives ISO 13485:2003 Certification 2Breckenridge Pharmaceutical signs Multi-Product Generic Agreement with Pharmaceutics International, Inc. 2Halozyme Therapeutics To Present At The Piper Jaffray Healthcare Conference 2
... , RIVIERA BEACH, Fla., Dec. 14 Perry Baromedical, international ... launch of the Sigma Elite, with extended patient data capture ... on each monoplace chamber model currently available ( www.perrybaromedical.com ) ... "Smart Hyperbaric System" includes: , Data Capture Via Computerized ...
... Dec. 14 Sword Diagnostics, Inc. is pleased to ... has issued patent number 7,599,057 titled "Method and Apparatus ... the company. The patent covers the core technology which ... this patent supports the underlying strategy as we move ...
Cached Medicine Technology:Perry Baromedical Announces New Cutting Edge Technology With Patient Data Capture Capability 2
(Date:11/27/2014)... DressVe , the well-known trendy young women’s clothing retailer, has ... Nov. 29 – Dec. 3 2014. In the special offer, ... 90% off. In addition, free delivery is provided for the ... , Dresses that combine trendy styles and high quality ... and figure. The designers of DressVe.com know this point very ...
(Date:11/27/2014)... This is a professional and in-depth study on ... a focus on the Chinese market. The report provides ... manufacturers and is a valuable source of guidance and ... , Firstly, the report provides a basic overview of ... Then, the report explores the international and Chinese major ...
(Date:11/27/2014)... November 28, 2014 The American Society for ... social media campaign in honor of World AIDS Day 2014. ... tested. Find a cure.” icon and infographic designed to generate ... getting tested for HIV. , ASCP has asked members to ... “Give a minute. Get Tested. Find a cure.” icon and ...
(Date:11/27/2014)... 27, 2014 According to a recent ... looking to break into the surgical robotics market ... other than the MIS field dominated by Intuitive. These ... U.S. surgical robotics market by 2020. , “The ... Kamran Zamanian, CEO and President of iData. “System sales ...
(Date:11/27/2014)... 2014 In a world enveloped ... sleep has lessened, and due to the intrusion ... of sleep has eroded. According to Web MD, ... job (Reference: http://www.webmd.com/sleep-disorders/features/sleep-deprivation-workplace ). This remarkably high ... an incalculable amount, leading not only to dissatisfied ...
Breaking Medicine News(10 mins):Health News:DressVe.com Introduces Its 2014 Special Monday Sales To The Global Customers 2Health News:Bronchoscopes Industry 2019 Forecasts for Global and China Region in New Research Report at ReportsnReports.com 2Health News:Bronchoscopes Industry 2019 Forecasts for Global and China Region in New Research Report at ReportsnReports.com 3Health News:ASCP Launches Social Media Campaign in Honor of World AIDS Day 2Health News:U.S. Robotic Surgery Market Set to Diversify and Grow: Intuitive Surgical’s ‘da Vinci’ Robot Revenues to Increasingly Rely On Procedures and Services 2Health News:Research Shows Surprising Number of US Workers Affected by Lack of Sleep 2
... of people are disappointed that the condom has not served ... sex, which defeats the goal of using condoms. ... for the FPA, Family Planning association, and the findings revealed ... reasons for ineffective use of condoms. As much as 43% ...
... the US U.S. doctors often misdiagnose tuberculosis due to ... suffer for years.// ,Tuberculosis is among the ... to the World Health Organization, has taken the lives ... tuberculosis bacterium has the ability to remain dormant for ...
... air sterilization technology that the U.S. Department of Defense ... may be protecting hospital patients from deadly infections, thanks ... of Science, Technology and Academic Research (NYSTAR). ,The ... becoming increasingly difficult to treat, are on the rise. ...
... known; a bite on the body that allows the virus ... happens next that causes the virus //to multiply and take ... Medical Institute (HHMI) international scholar in Argentina have been able ... virus multiply, which is the main cause of the potentially ...
... by the stem cells researchers across the world and ... Illumina Inc., it was found that embryonic stem cell ... totipotent. ,This sets aside the embryonic stem ... These characteristics could be later used to replace diseased ...
... Treatment Trial (NETT) it was found that emphysema patients ... ,The bilateral lung volume reduction surgery (LVRS) to ... among these patients. NETT researchers describe the effects of ... 4.3 years, two years longer than the primary results ...
Cached Medicine News:Health News:Doctors In US Lack Skills For The Diagnosis Of TB 2Health News:Device Can "Battle" Hospital Infections 2Health News:Device Can "Battle" Hospital Infections 3Health News:The Dengue Virus Unplugged 2Health News:The Dengue Virus Unplugged 3Health News:Human Embryonic Stem Cells Could Be Later Used In Therapeutic Cloning 2
The K-ASSAY Anti-Streptolysin O Control Set is intended to be used as a consistent test sample of known concentration for monitoring the performance of K-ASSAY immunoturbidimetric assay for quantifyi...
Eppendorf expands its line of benchtop microcentrifuges with the 5418. This easy-to-use microcentrifuge features a certified aerosol-tight rotor and a unique, contoured rotor bowl design to reduce no...
... The Directigen EZ Flu A+B test ... direct and qualitative detection of influenza A ... and throat swabs of symptomatic patients. The ... differentiated test, such that influenza A viral ...
... Mid-Urethral Sling System is intended to ... sling for the treatment of stress ... an innovative mid-urethral sling that offers ... all of which are designed to ...
Medicine Products: